We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 565478


Description: BTZ is a novel covalent probe of recombinant and endogenous bromodomain-containing proteins, targeting a conserved lysine and a tyrosine residue in the variable za or bc loops

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-04-07. Prices are subject to change without notice.

BTZ is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 565478
Name: BTZ
Chemical Formula: C21H17Cl2N9O2
Exact Mass: 497.0882
Molecular Weight: 498.328
Elemental Analysis: C, 50.62; H, 3.44; Cl, 14.23; N, 25.30; O, 6.42

Synonym: BTZ

IUPAC/Chemical Name: But-3-yn-1-yl (6-(3-((4,6-dichloro-1,3,5-triazin-2-yl)amino)-4-methylphenyl)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-yl)carbamate


InChi Code: InChI=1S/C21H17Cl2N9O2/c1-4-5-8-34-21(33)25-16-10-15(31-32-12(3)29-30-17(16)32)13-7-6-11(2)14(9-13)24-20-27-18(22)26-19(23)28-20/h1,6-7,9-10H,5,8H2,2-3H3,(H,25,33)(H,24,26,27,28)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Manola MS, Tsakiri EN, Trougakos IP. Alterations in Organismal Physiology, Impaired Stress Resistance, and Accelerated Aging in Drosophila Flies Adapted to Multigenerational Proteome Instability. Oxid Med Cell Longev. 2019 Jun 11;2019:7823285. doi: 10.1155/2019/7823285. eCollection 2019. PubMed PMID: 31320986; PubMed Central PMCID: PMC6610734.

2: Gras Navarro A, Espedal H, Joseph JV, Trachsel-Moncho L, Bahador M, Tore Gjertsen B, Klæboe Kristoffersen E, Simonsen A, Miletic H, Øyvind Enger P, Rahman MA, Chekenya M. Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival. Cancers (Basel). 2019 Jul 17;11(7). pii: E996. doi: 10.3390/cancers11070996. PubMed PMID: 31319548.

3: Hafez H, Kamal R. Photovoltaic and spectroscopic characteristics of perovskite/TiO(2) heterostructure photoanodes for improving the efficiency of dye sensitized solar cells. Spectrochim Acta A Mol Biomol Spectrosc. 2019 Jun 3;222:117220. doi: 10.1016/j.saa.2019.117220. [Epub ahead of print] PubMed PMID: 31226614.

4: Zhao Y, Huang G, Wu J, Wu Q, Gao S, Yan Z, Lei J, Yan N. Molecular Basis for Ligand Modulation of a Mammalian Voltage-Gated Ca(2+) Channel. Cell. 2019 May 30;177(6):1495-1506.e12. doi: 10.1016/j.cell.2019.04.043. PubMed PMID: 31150622.

5: Delgado-Calle J, Kurihara N, Atkinson EG, Nelson J, Miyagawa K, Galmarini CM, Roodman GD, Bellido T. Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts. Oncotarget. 2019 Apr 12;10(28):2709-2721. doi: 10.18632/oncotarget.26831. eCollection 2019 Apr 12. PubMed PMID: 31105871; PubMed Central PMCID: PMC6505631.

6: Korani M, Ghaffari S, Attar H, Mashreghi M, Jaafari MR. Preparation and characterization of nanoliposomal bortezomib formulations and evaluation of their anti-cancer efficacy in mice bearing C26 colon carcinoma and B16F0 melanoma. Nanomedicine. 2019 May 16;20:102013. doi: 10.1016/j.nano.2019.04.016. [Epub ahead of print] PubMed PMID: 31103736.

7: Nian F, Zhu J, Chang H. Long non-coding RNA ANGPTL1-3 promotes multiple myeloma bortezomib resistance by sponging miR-30a-3p to activate c-Maf expression. Biochem Biophys Res Commun. 2019 Jul 5;514(4):1140-1146. doi: 10.1016/j.bbrc.2019.05.078. Epub 2019 May 15. PubMed PMID: 31103265.

8: Qian Y, Zhang Y, Wang Z, Yin J, Peng Z, Zhou G. [Determination of five cholesterol oxidation products in marinated pig feet and hocks by gas chromatography-mass spectrometry]. Se Pu. 2019 May 8;37(5):539-546. doi: 10.3724/SP.J.1123.2018.11020. Chinese. PubMed PMID: 31070338.

9: Tang J, Chen Q, Zhang F, Zhang W, Duan S, Xiao D. [Peripheral blood exosomes from patients with multiple myeloma mediate bortezomib resistance in cultured multiple myeloma cells]. Nan Fang Yi Ke Da Xue Xue Bao. 2019 Apr 30;39(4):485-489. doi: 10.12122/j.issn.1673-4254.2019.04.16. Chinese. PubMed PMID: 31068294.

10: Akhtar S, Achkar IW, Siveen KS, Kuttikrishnan S, Prabhu KS, Khan AQ, Ahmed EI, Sahir F, Jerobin J, Raza A, Merhi M, Elsabah HM, Taha R, Omri HE, Zayed H, Dermime S, Steinhoff M, Uddin S. Sanguinarine Induces Apoptosis Pathway in Multiple Myeloma Cell Lines via Inhibition of the JaK2/STAT3 Signaling. Front Oncol. 2019 Apr 17;9:285. doi: 10.3389/fonc.2019.00285. eCollection 2019. PubMed PMID: 31058086; PubMed Central PMCID: PMC6478801.

11: Huang FI, Wu YW, Sung TY, Liou JP, Lin MH, Pan SL, Yang CR. MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells. Front Oncol. 2019 Apr 9;9:249. doi: 10.3389/fonc.2019.00249. eCollection 2019. PubMed PMID: 31024851; PubMed Central PMCID: PMC6465934.

12: Luanpitpong S, Janan M, Thumanu K, Poohadsuan J, Rodboon N, Klaihmon P, Issaragrisil S. Deciphering the Elevated Lipid via CD36 in Mantle Cell Lymphoma with Bortezomib Resistance Using Synchrotron-Based Fourier Transform Infrared Spectroscopy of Single Cells. Cancers (Basel). 2019 Apr 24;11(4). pii: E576. doi: 10.3390/cancers11040576. PubMed PMID: 31022903; PubMed Central PMCID: PMC6521097.

13: Heitmeier T, Sydykov A, Lukas C, Vroom C, Korfei M, Petrovic A, Klingel K, Günther A, Eickelberg O, Weissmann N, Ghofrani HA, Seeger W, Grimminger F, Schermuly RT, Meiners S, Kosanovic D. Altered proteasome function in right ventricular hypertrophy. Cardiovasc Res. 2019 Apr 24. pii: cvz103. doi: 10.1093/cvr/cvz103. [Epub ahead of print] PubMed PMID: 31020333.

14: Li YP, Zhang JG, Fang ZQ, Huang XR, Chen X, Li ZJ, Fang J. [Effect of Bushen Yanggu Decoction on Multidrug Resistance of Multiple Myeloma Cell Line KM3/BTZ]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Apr;27(2):482-488. doi: 10.19746/j.cnki.issn.1009-2137.2019.02.028. Chinese. PubMed PMID: 30998158.

15: Moschetti G, Amodeo G, Maftei D, Lattanzi R, Procacci P, Sartori P, Balboni G, Onnis V, Conte V, Panerai A, Sacerdote P, Franchi S. Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy. J Neuroinflammation. 2019 Apr 17;16(1):89. doi: 10.1186/s12974-019-1461-0. PubMed PMID: 30995914; PubMed Central PMCID: PMC6471808.

16: Guo H, Huang B, Zhang L, Chen L, Xie Q, Liao Z, Huang S, Chen Y. Double Acceptor Block-Containing Copolymers with Deep HOMO Levels for Organic Solar Cells: Adjusting Carboxylate Substituent Position for Planarity. ACS Appl Mater Interfaces. 2019 May 1;11(17):15853-15860. doi: 10.1021/acsami.9b02212. Epub 2019 Apr 23. PubMed PMID: 30987420.

17: Homma T, Fujii J. An SOD1 deficiency aggravates proteasome inhibitor bortezomib-induced testicular damage in mice. Biochim Biophys Acta Gen Subj. 2019 Jun;1863(6):1108-1115. doi: 10.1016/j.bbagen.2019.04.005. Epub 2019 Apr 8. PubMed PMID: 30974160.

18: Fu Y, Liu X, Zhang F, Jiang S, Liu J, Luo Y. Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b. Cell Death Dis. 2019 Apr 9;10(4):319. doi: 10.1038/s41419-019-1551-z. PubMed PMID: 30967527; PubMed Central PMCID: PMC6456577.

19: Brünnert D, Kraus M, Stühmer T, Kirner S, Heiden R, Goyal P, Driessen C, Bargou RC, Chatterjee M. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma. Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1666-1676. doi: 10.1016/j.bbadis.2019.04.003. Epub 2019 Apr 4. PubMed PMID: 30954557.

20: Gao N, Xing C, Wang H, Feng L, Zeng X, Mei L, Peng Z. pH-Responsive Dual Drug-Loaded Nanocarriers Based on Poly (2-Ethyl-2-Oxazoline) Modified Black Phosphorus Nanosheets for Cancer Chemo/Photothermal Therapy. Front Pharmacol. 2019 Mar 19;10:270. doi: 10.3389/fphar.2019.00270. eCollection 2019. PubMed PMID: 30941045; PubMed Central PMCID: PMC6433829.